Quinazoline-7-ether compounds and methods of use
US9187459B2 · kind B2 · utility
1Cited by
17References
29Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 17, 2012 |
| Grant date | Nov 17, 2015 |
| Priority date | — |
| Expiry date | May 17, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D493/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides quinazoline-7-ether derivatives, particularly 4-anilinyl-6-butenamido-quinazoline-7-ether derivatives that are inhibitors of the receptor protein tyrosine kinases (RTK). The compounds are useful in the treatment of diseases and disorders where RTK activity is implicated such as a hyperproliferative diseases (e.g., cancer). Also provided are methods of preparation of the quinazoline derivatives and methods of use as therapeutic agents alone or in a drug combination.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.